These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 33766811

  • 1. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE, Rosenbaum DP, Yang Y, Chertow GM.
    J Am Soc Nephrol; 2021 Jun 01; 32(6):1465-1473. PubMed ID: 33766811
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
    Block GA, Rosenbaum DP, Yan A, Chertow GM.
    J Am Soc Nephrol; 2019 Apr 01; 30(4):641-652. PubMed ID: 30846557
    [Abstract] [Full Text] [Related]

  • 4. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
    Block GA, Bleyer AJ, Silva AL, Weiner DE, Lynn RI, Yang Y, Rosenbaum DP, Chertow GM.
    Kidney360; 2021 Oct 28; 2(10):1600-1610. PubMed ID: 35372979
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]

  • 10. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
    Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, Smith AR, Zee J, Karaboyas A, Bieber B, Fukagawa M, Tentori F.
    Clin J Am Soc Nephrol; 2017 Sep 07; 12(9):1489-1497. PubMed ID: 28724618
    [Abstract] [Full Text] [Related]

  • 11. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
    Zhuang B, Gan L, Liu B, Yuan W, Shi M, Peng A, Wang L, Chen X, Liu T, Zhang S, Wang S, Gao Q, Wang B, Zheng H, Liu C, Luo Y, Ye H, Lin H, Li Y, He Q, Zheng F, Luo P, Long G, Lu W, Li K, Yang J, Liu YC, Zhang Z, Li X, Zhang W, Zuo L.
    Nephrol Dial Transplant; 2024 Sep 27; 39(10):1649-1661. PubMed ID: 38453435
    [Abstract] [Full Text] [Related]

  • 12. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
    Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Stefansson BV, Rydén-Bergsten T, Greasley PJ, Johansson SA, Knutsson M, Carlsson BC.
    Clin J Am Soc Nephrol; 2016 Sep 07; 11(9):1597-1605. PubMed ID: 27340281
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J.
    Nephron; 2020 Sep 07; 144(9):428-439. PubMed ID: 32585670
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis.
    Yu S, Sun J, Guo X.
    Ren Fail; 2024 Dec 07; 46(2):2410389. PubMed ID: 39351794
    [Abstract] [Full Text] [Related]

  • 15. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep 07; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 16. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, PA21 Study Group.
    Kidney Int; 2014 Sep 07; 86(3):638-47. PubMed ID: 24646861
    [Abstract] [Full Text] [Related]

  • 17. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
    Yee J, Rosenbaum D, Jacobs JW, Sprague SM.
    Am J Nephrol; 2021 Sep 07; 52(7):522-530. PubMed ID: 34515051
    [Abstract] [Full Text] [Related]

  • 18. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.
    Am J Kidney Dis; 2016 Nov 07; 68(5S1):S24-S32. PubMed ID: 27772640
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kanoh H.
    Ther Apher Dial; 2014 Jun 07; 18 Suppl 2():24-32. PubMed ID: 24975892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.